The prevalence of asthma has been increasing, affecting more than 300 million
patients worldwide,1 including 5.4 million in the UK alone – one in 11 people.2
Each day, 185 people in the UK are admitted to hospital with an exacerbation of their
asthma with, on average, 3 people a day dying as a result.2 Overall, 1,320 asthma
deaths were reported in England and Wales in 2017, up 25% in the past decade3
and in Scotland asthma related deaths were reported as 133 in 2016.4
Asthma has no single cause. Genetic predisposition is clear from the literature,
however gene-by-environment interaction is likely to be responsible for the
global variation in asthma prevalence.
Asthma presents in a heterogeneous way but can be categorised into two
forms: Type 2 asthma (driven by type 2 inflammation) and non-Type 2 asthma.
Within these two divisions are further subdivisions, known as “phenotypes”.
Asthma is a heterogeneous chronic respiratory disease affecting millions of adults and children worldwide11Facts & figures
Patients with uncontrolled persistent asthma may also
experience impaired lung function, risk of long-term
side effects, and poor QoL13–17
Various comorbidities are often associated with asthma. These can influence the clinical expression of asthma, alter asthma responses to therapy and ultimately reduce a patient’s QoL18Explore the data
Explore the key drivers of Type 2 inflammationSee the science
CD4+, cluster of differentiation 4-positive T cell; IgE, immunoglobulin E; IL, interleukin; ILCs, innate lymphoid cells; ILC2, type 2 innate lymphoid cells; QoL, quality of life; Th, T helper cells.References: